Published in J Virol on June 01, 1998
Viral late domains. J Virol (2002) 4.51
Ubiquitin is part of the retrovirus budding machinery. Proc Natl Acad Sci U S A (2000) 3.83
Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain. J Virol (2000) 3.77
Multimerization of human immunodeficiency virus type 1 Gag promotes its localization to barges, raft-like membrane microdomains. J Virol (2001) 2.82
The late domain of human immunodeficiency virus type 1 p6 promotes virus release in a cell type-dependent manner. J Virol (2002) 2.66
Organization of immature human immunodeficiency virus type 1. J Virol (2001) 2.34
Head-to-tail dimers and interdomain flexibility revealed by the crystal structure of HIV-1 capsid protein (p24) complexed with a monoclonal antibody Fab. EMBO J (1999) 2.33
Mass determination of rous sarcoma virus virions by scanning transmission electron microscopy. J Virol (1999) 2.15
Second-site suppressors of Rous sarcoma virus Ca mutations: evidence for interdomain interactions. J Virol (2001) 1.55
The retroviral capsid domain dictates virion size, morphology, and coassembly of gag into virus-like particles. J Virol (2005) 1.52
Mutational analysis of the hydrophobic tail of the human immunodeficiency virus type 1 p6(Gag) protein produces a mutant that fails to package its envelope protein. J Virol (1999) 1.25
Identification of retroviral late domains as determinants of particle size. J Virol (1999) 1.25
Role of RNA in facilitating Gag/Gag-Pol interaction. J Virol (2002) 1.25
Functional roles of equine infectious anemia virus Gag p9 in viral budding and infection. J Virol (2001) 1.24
Rapid localization of Gag/GagPol complexes to detergent-resistant membrane during the assembly of human immunodeficiency virus type 1. J Virol (2003) 1.23
Proline residues in human immunodeficiency virus type 1 p6(Gag) exert a cell type-dependent effect on viral replication and virion incorporation of Pol proteins. J Virol (1999) 1.23
RNA incorporation is critical for retroviral particle integrity after cell membrane assembly of Gag complexes. J Virol (2002) 1.21
Conditions for copackaging rous sarcoma virus and murine leukemia virus Gag proteins during retroviral budding. J Virol (1999) 1.07
Analysis of Mason-Pfizer monkey virus Gag domains required for capsid assembly in bacteria: role of the N-terminal proline residue of CA in directing particle shape. J Virol (2000) 1.06
Nucleocapsid-RNA interactions are essential to structural stability but not to assembly of retroviruses. J Virol (2004) 1.05
The NH2-terminal domain of the human T-cell leukemia virus type 1 capsid protein is involved in particle formation. J Virol (2001) 0.92
Incorporation of pol into human immunodeficiency virus type 1 Gag virus-like particles occurs independently of the upstream Gag domain in Gag-pol. J Virol (2004) 0.88
Sustained, localized transgene expression mediated from lentivirus-loaded biodegradable polyester elastomers. J Biomed Mater Res A (2012) 0.79
Contributions of Charged Residues in Structurally Dynamic Capsid Surface Loops to Rous Sarcoma Virus Assembly. J Virol (2016) 0.76
Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A (1988) 10.77
A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature (1993) 10.36
Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc Natl Acad Sci U S A (1991) 10.05
Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell (1989) 9.68
A nucleoprotein complex mediates the integration of retroviral DNA. Genes Dev (1989) 8.80
Mutations of RNA and protein sequences involved in human immunodeficiency virus type 1 packaging result in production of noninfectious virus. J Virol (1990) 7.90
p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. J Virol (1995) 6.87
Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids. J Virol (1994) 6.67
Point mutants of Moloney murine leukemia virus that fail to package viral RNA: evidence for specific RNA recognition by a "zinc finger-like" protein sequence. Proc Natl Acad Sci U S A (1988) 6.44
Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. Proc Natl Acad Sci U S A (1993) 6.44
An assembly domain of the Rous sarcoma virus Gag protein required late in budding. J Virol (1994) 5.87
The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions. J Virol (1992) 5.30
Self-assembly in vitro of purified CA-NC proteins from Rous sarcoma virus and human immunodeficiency virus type 1. J Virol (1995) 5.21
Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J Virol (1989) 5.15
Positionally independent and exchangeable late budding functions of the Rous sarcoma virus and human immunodeficiency virus Gag proteins. J Virol (1995) 4.92
Creation and expression of myristylated forms of Rous sarcoma virus gag protein in mammalian cells. J Virol (1989) 4.60
The WW domain of Yes-associated protein binds a proline-rich ligand that differs from the consensus established for Src homology 3-binding modules. Proc Natl Acad Sci U S A (1995) 4.52
Role of the matrix protein in the virion association of the human immunodeficiency virus type 1 envelope glycoprotein. J Virol (1994) 4.28
Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector. Proc Natl Acad Sci U S A (1989) 4.26
Suppression of retroviral MA deletions by the amino-terminal membrane-binding domain of p60src. J Virol (1991) 4.25
Mapping of functionally important residues of a cysteine-histidine box in the human immunodeficiency virus type 1 nucleocapsid protein. J Virol (1993) 4.22
An N-terminal peptide from p60src can direct myristylation and plasma membrane localization when fused to heterologous proteins. Nature (1985) 4.06
Identification of human immunodeficiency virus type 1 Gag protein domains essential to membrane binding and particle assembly. J Virol (1994) 3.85
The spacer peptide between human immunodeficiency virus capsid and nucleocapsid proteins is essential for ordered assembly and viral infectivity. J Virol (1995) 3.80
Assembly, processing, and infectivity of human immunodeficiency virus type 1 gag mutants. J Virol (1993) 3.75
Functional chimeras of the Rous sarcoma virus and human immunodeficiency virus gag proteins. J Virol (1993) 3.71
Cryo-electron microscopy reveals ordered domains in the immature HIV-1 particle. Curr Biol (1997) 3.59
Functional domains of the capsid protein of human immunodeficiency virus type 1. J Virol (1994) 3.47
Incorporation of chimeric gag protein into retroviral particles. J Virol (1990) 3.43
Characterization of a small (25-kilodalton) derivative of the Rous sarcoma virus Gag protein competent for particle release. J Virol (1993) 3.19
Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression. J Virol (1992) 3.14
WW domains and retrovirus budding. Nature (1996) 3.10
Distinct signals in human immunodeficiency virus type 1 Pr55 necessary for RNA binding and particle formation. J Gen Virol (1992) 2.89
Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles. Virology (1993) 2.81
The p6gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles. J Virol (1995) 2.64
Linker insertion mutations in the human immunodeficiency virus type 1 gag gene: effects on virion particle assembly, release, and infectivity. J Virol (1995) 2.56
Failure of a human immunodeficiency virus (HIV) immune globulin to protect chimpanzees against experimental challenge with HIV. Proc Natl Acad Sci U S A (1988) 2.47
The role of Gag in human immunodeficiency virus type 1 virion morphogenesis and early steps of the viral life cycle. J Virol (1996) 2.31
Role of the avian retroviral protease in the activation of reverse transcriptase during virion assembly. J Virol (1991) 2.23
Functional domains of HIV-1 gag-polyprotein expressed in baculovirus-infected cells. Virology (1991) 2.13
Role of the gag and pol genes of human immunodeficiency virus in the morphogenesis and maturation of retrovirus-like particles expressed by recombinant vaccinia virus: an ultrastructural study. J Gen Virol (1991) 2.05
Phenotypic characterization of insertion mutants of the human immunodeficiency virus type 1 Gag precursor expressed in recombinant baculovirus-infected cells. J Virol (1994) 1.99
A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles. J Virol (1995) 1.93
Characterization of deletion mutations in the capsid region of human immunodeficiency virus type 1 that affect particle formation and Gag-Pol precursor incorporation. J Virol (1995) 1.73
Evidence for a second function of the MA sequence in the Rous sarcoma virus Gag protein. J Virol (1996) 1.70
Genetic determinants of Rous sarcoma virus particle size. J Virol (1998) 1.67
Biological techniques for avian sarcoma viruses. Methods Enzymol (1979) 1.67
Comparative morphology of Gag protein structures produced by mutants of the gag gene of human immunodeficiency virus type 1. J Gen Virol (1994) 1.65
Analysis of protein expression and virus-like particle formation in mammalian cell lines stably expressing HIV-1 gag and env gene products with or without active HIV proteinase. Virology (1993) 1.33
Altered Rous sarcoma virus Gag polyprotein processing and its effects on particle formation. J Virol (1997) 1.05
Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature (1985) 30.62
Form, function, and use of retroviral gag proteins. AIDS (1991) 9.24
A molecular clone of HTLV-III with biological activity. Nature (1985) 8.30
Myristoylation-dependent replication and assembly of human immunodeficiency virus 1. Proc Natl Acad Sci U S A (1990) 8.23
Complete nucleotide sequences of functional clones of the AIDS virus. AIDS Res Hum Retroviruses (1987) 7.85
The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci U S A (1994) 7.85
Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol (2000) 6.71
Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids. J Virol (1994) 6.67
The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science (1987) 6.16
Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes. Proc Natl Acad Sci U S A (1991) 5.26
Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo. J Virol (1992) 5.19
Positionally independent and exchangeable late budding functions of the Rous sarcoma virus and human immunodeficiency virus Gag proteins. J Virol (1995) 4.92
DNA content, kinetic complexity, and the ploidy question in Candida albicans. Mol Cell Biol (1982) 4.64
Infectious mutants of HTLV-III with changes in the 3' region and markedly reduced cytopathic effects. Science (1986) 4.17
Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions. J Virol (1993) 4.16
Equine infectious anemia virus utilizes a YXXL motif within the late assembly domain of the Gag p9 protein. J Virol (1997) 4.08
Fine mapping and characterization of the Rous sarcoma virus Pr76gag late assembly domain. J Virol (1996) 3.97
Identification of human immunodeficiency virus type 1 Gag protein domains essential to membrane binding and particle assembly. J Virol (1994) 3.85
Ubiquitin is part of the retrovirus budding machinery. Proc Natl Acad Sci U S A (2000) 3.83
Functional chimeras of the Rous sarcoma virus and human immunodeficiency virus gag proteins. J Virol (1993) 3.71
Human immunodeficiency virus type 1 negative factor is a transcriptional silencer. Proc Natl Acad Sci U S A (1989) 3.65
Incorporation of chimeric gag protein into retroviral particles. J Virol (1990) 3.43
Relationship of human immunodeficiency virus type 1 sequence heterogeneity to stage of disease. Proc Natl Acad Sci U S A (1992) 3.19
Characterization of a small (25-kilodalton) derivative of the Rous sarcoma virus Gag protein competent for particle release. J Virol (1993) 3.19
Transactivation induced by human T-lymphotropic virus type III (HTLV III) maps to a viral sequence encoding 58 amino acids and lacks tissue specificity. Virology (1986) 3.15
Mutations of the Rous sarcoma virus env gene that affect the transport and subcellular location of the glycoprotein products. J Cell Biol (1984) 3.11
WW domains and retrovirus budding. Nature (1996) 3.10
Identification of tRNAs incorporated into wild-type and mutant human immunodeficiency virus type 1. J Virol (1993) 3.08
Membrane binding of human immunodeficiency virus type 1 matrix protein in vivo supports a conformational myristyl switch mechanism. J Virol (1997) 3.07
Late domain function identified in the vesicular stomatitis virus M protein by use of rhabdovirus-retrovirus chimeras. J Virol (1999) 2.90
Genetic analysis of the major homology region of the Rous sarcoma virus Gag protein. J Virol (1995) 2.76
Dual regulation of silent and productive infection in monocytes by distinct human immunodeficiency virus type 1 determinants. J Virol (1992) 2.62
Characterization of long terminal repeat sequences of HTLV-III. Science (1985) 2.56
Viral protein R regulates nuclear import of the HIV-1 pre-integration complex. EMBO J (1998) 2.56
Repetitive DNA of Candida albicans: nuclear and mitochondrial components. J Bacteriol (1984) 2.52
Development of leukemia in mice transgenic for the tax gene of human T-cell leukemia virus type I. Proc Natl Acad Sci U S A (1995) 2.43
Necessity of the spacer peptide between CA and NC in the Rous sarcoma virus gag protein. J Virol (1993) 2.40
Amino acids encoded downstream of gag are not required by Rous sarcoma virus protease during gag-mediated assembly. J Virol (1991) 2.38
Human-proto-oncogene nucleotide sequences corresponding to the transforming region of simian sarcoma virus. Science (1984) 2.32
Viral protein R of human immunodeficiency virus types 1 and 2 is dispensable for replication and cytopathogenicity in lymphoid cells. J Virol (1989) 2.28
Role of the avian retroviral protease in the activation of reverse transcriptase during virion assembly. J Virol (1991) 2.23
Interferon action: two distinct pathways for inhibition of protein synthesis by double-stranded RNA. Proc Natl Acad Sci U S A (1978) 2.22
Importance of basic residues in the nucleocapsid sequence for retrovirus Gag assembly and complementation rescue. J Virol (1998) 2.18
Construction and characterization of infectious human T-cell leukemia virus type 1 molecular clones. Virology (1994) 2.14
HTLV-III, LAV, ARV are variants of same AIDS virus. Nature (1985) 2.03
Selective ablation of human T-cell lymphotropic virus type 1 p12I reduces viral infectivity in vivo. Blood (1998) 2.03
Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization. J Virol (1999) 2.02
Polymorphism of the 3' open reading frame of the virus associated with the acquired immune deficiency syndrome, human T-lymphotropic virus type III. Nucleic Acids Res (1985) 2.01
Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. J Virol (2006) 2.00
Immortalization of CD4(+) and CD8(+) T lymphocytes by human T-cell leukemia virus type 1 Tax mutants expressed in a functional molecular clone. J Virol (1999) 1.94
A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles. J Virol (1995) 1.93
Sequences of the 5' portion of the human c-sis gene: characterization of the transcriptional promoter and regulation of expression of the protein product by 5' untranslated mRNA sequences. Nucleic Acids Res (1987) 1.91
Intracellular trafficking of the UL11 tegument protein of herpes simplex virus type 1. J Virol (2001) 1.90
Circular mitochondrial genome of Candida albicans contains a large inverted duplication. J Bacteriol (1985) 1.84
Transformation of NIH 3T3 cells by a human c-sis cDNA clone. Nature (1984) 1.73
Multidrug resistance transporters and modulation. Curr Opin Oncol (2000) 1.71
Evidence for a second function of the MA sequence in the Rous sarcoma virus Gag protein. J Virol (1996) 1.70
Efficiency and selectivity of RNA packaging by Rous sarcoma virus Gag deletion mutants. J Virol (1994) 1.70
Interferon, double-stranded RNA and RNA degradation. Fractionation of the endonucleaseINT system into two macromolecular components; role of a small molecule in nuclease activation. Biochem Biophys Res Commun (1978) 1.70
Deletion of 5'-coding sequences of the cellular p53 gene in mouse erythroleukemia: a novel mechanism of oncogene regulation. Mol Cell Biol (1987) 1.69
Viral protein R regulates docking of the HIV-1 preintegration complex to the nuclear pore complex. J Biol Chem (1998) 1.68
Genetic determinants of Rous sarcoma virus particle size. J Virol (1998) 1.67
Role of the carboxy-terminal portion of the HIV-1 transmembrane protein in viral transmission and cytopathogenicity. AIDS Res Hum Retroviruses (1989) 1.67
Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein. Nat Med (1999) 1.63
Functional role of pX open reading frame II of human T-lymphotropic virus type 1 in maintenance of viral loads in vivo. J Virol (2000) 1.61
Human immunodeficiency virus type 1 Nef protein inhibits NF-kappa B induction in human T cells. J Virol (1992) 1.59
Transforming potential of human c-sis nucleotide sequences encoding platelet-derived growth factor. Science (1984) 1.58
Second-site suppressors of Rous sarcoma virus Ca mutations: evidence for interdomain interactions. J Virol (2001) 1.55
Human immunodeficiency virus type 1 tropism for T-lymphoid cell lines: role of the V3 loop and C4 envelope determinants. J Virol (1996) 1.55
Limited sequence heterogeneity among biologically distinct human immunodeficiency virus type 1 isolates from individuals involved in a clustered infectious outbreak. Proc Natl Acad Sci U S A (1990) 1.54
Human T-cell leukemia virus type 1 pX-I and pX-II open reading frames are dispensable for the immortalization of primary lymphocytes. J Virol (1998) 1.52
Replication of human immunodeficiency virus 1 and Moloney murine leukemia virus is inhibited by different heteroatom-containing analogs of myristic acid. Proc Natl Acad Sci U S A (1989) 1.47
Recent advances and remaining problems in HIV assembly. AIDS (1998) 1.46
Cooperative effects of the human immunodeficiency virus type 1 envelope variable loops V1 and V3 in mediating infectivity for T cells. J Virol (1996) 1.45
A large region within the Rous sarcoma virus matrix protein is dispensable for budding and infectivity. J Virol (1996) 1.43
Analysis of the function of viral protein X (VPX) of HIV-2. Virology (1989) 1.42
The membrane-binding domain of the Rous sarcoma virus Gag protein. J Virol (1996) 1.39
Membrane targeting properties of a herpesvirus tegument protein-retrovirus Gag chimera. J Virol (2000) 1.36
Myristylation of Rous sarcoma virus Gag protein does not prevent replication in avian cells. J Virol (1990) 1.36
A common protein binds to two silencers 5' to the human beta-globin gene. Nucleic Acids Res (1989) 1.36
HIV-2 viral protein X association with the GAG p27 capsid protein. Virology (1994) 1.35
Human T-lymphotropic virus type 1 open reading frame I p12(I) is required for efficient viral infectivity in primary lymphocytes. J Virol (2000) 1.34
Repositioning basic residues in the M domain of the Rous sarcoma virus gag protein. J Virol (2000) 1.33
In vitro CD4+ lymphocyte transformation and infection in a rabbit model with a molecular clone of human T-cell lymphotrophic virus type 1. J Virol (1996) 1.33
Actin cytoskeletal reorganizations and coreceptor-mediated activation of rac during human immunodeficiency virus-induced cell fusion. J Virol (2004) 1.32
Myristoylation-enhanced binding of the HIV-1 Nef protein to T cell skeletal matrix. Virology (1993) 1.32
Alterations in the transport and processing of Rous sarcoma virus envelope glycoproteins mutated in the signal and anchor regions. J Cell Biochem (1983) 1.31
The C-terminal proline-rich tail of human immunodeficiency virus type 2 Vpx is necessary for nuclear localization of the viral preintegration complex in nondividing cells. J Virol (2000) 1.29
Loss of a highly conserved domain on p53 as a result of gene deletion during Friend virus-induced erythroleukemia. Oncogene (1988) 1.28
Human immunodeficiency virus type 1 capsid formation in reticulocyte lysates. J Virol (1996) 1.27
Incorporation of 12-methoxydodecanoate into the human immunodeficiency virus 1 gag polyprotein precursor inhibits its proteolytic processing and virus production in a chronically infected human lymphoid cell line. Proc Natl Acad Sci U S A (1991) 1.27
Identification of retroviral late domains as determinants of particle size. J Virol (1999) 1.25
Limited sequence variation in human T-lymphotropic virus type 1 isolates from North American and African patients. Virology (1991) 1.24
Nucleotide sequence analysis of a variant human T-cell leukemia virus (HTLV-Ib) provirus with a deletion in pX-I. J Virol (1985) 1.23
Amino-terminal deletion mutants of the Rous sarcoma virus glycoprotein do not block signal peptide cleavage but can block intracellular transport. J Cell Biol (1986) 1.21
Isolation of virus-neutralizing RNAs from a large pool of random sequences. Proc Natl Acad Sci U S A (1995) 1.18